Related Experiment Video
Updated: Sep 13, 2026

In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease
Published on: July 19, 2024
Metabolic dysfunction-associated steatotic liver disease predicts graft failure in kidney transplant recipients
Kyungho Lee1, Yebin Park2, Hojin Jeon1
1Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Introduction:
Metabolic dysfunction-associated steatotic liver disease (MASLD) has been established to classify steatotic liver disease more accurately. We investigated the association between MASLD and long-term kidney transplant outcomes.
Methods:
Kidney transplant recipients who underwent national health screening programs from 2009 to 2017 and with follow-up until 2021 were identified using the Korean National Health Insurance Service data. MASLD was defined based on cardiometabolic criteria and the fatty liver index.
Results:
Among 8326 kidney transplant recipients, 2027 (24.3%) had MASLD, 25 (0.3%) had MASLD with increased alcohol intake, and 419 (5.0%) had MASLD with other liver diseases. The incidence rates of graft failure (17.5 vs. 11.3, P < .001) and mortality (12.5 vs. 8.9 per 1000 person-years, P < .001) were significantly higher in the MASLD group than in those without steatotic liver disease. After adjusting for demographics, lifestyle, comorbidities, estimated glomerular filtration rate, proteinuria, and acute rejection, the adjusted hazard ratios for graft failure and mortality were 1.23 (95% confidence interval, 1.03-1.46) and 1.03 (95% confidence interval, 0.85-1.25), respectively.
Conclusions:
This study identified MASLD as a significant risk factor for graft failure in kidney transplant recipients, highlighting the need for MASLD screening and management in kidney transplant recipients.
Related Concept Videos
Kidney Transplant I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Kidney Transplant II: Surgical Procedure
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
